AXS-05 is an investigational agent consisting of a proprietary formulation of dextromethorphan and bupropion. Results from a phase 3 trial evaluating AXS-05 in patients with Alzheimer disease ...
Managed care organization and providers should conduct early formulary reviews and education to ensure rapid access to dextromethorphan-bupropion upon approval, potentially delaying facility placement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results